Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 137

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 8
Chunk 137
---
 within a specified period of time. Once a foreign person (together with any associate) holds a direct interest
or a substantial interest in an entity, any further acquisition of interests, including in the course of trading in the secondary market,
would require a new FIRB approval unless an exemption applies.

Once granted, a FIRB approval
is valid for a 12 month period, meaning the proposed acquisition which was the subject of an application can occur any time during that
12 month period.

E. Taxation

The following is a discussion
of Australian and United States tax consequences material to our shareholders. To the extent that the discussion is based on tax legislation
which has not been subject to judicial or administrative interpretation, the views expressed in the discussion might not be accepted by
the tax authorities in question or by court. The discussion is not intended, and should not be construed, as legal or professional tax
advice and does not exhaust all possible tax considerations.

Holders of our ADSs should
consult their own tax advisors as to the United States, Australian or other tax consequences of the purchase, ownership and disposition
of ADSs, including, in particular, the effect of any foreign, state or local taxes.

U. S. Taxation

The following is a summary
of material U. S. federal income tax consequences that generally apply to U. S. Holders (as defined below) who hold ADSs as capital assets
within the meaning of Section 1221 of the Internal Revenue Code of 1986, as amended (the “ Code”). This summary is based
on the Code, its legislative history, final, temporary and proposed United States Treasury regulations promulgated thereunder, published
rulings and court decisions, and the bilateral income tax convention between Australia and the United States (the “ Treaty”),
all as in effect on the date hereof and all of which are subject to change, or changes in interpretation, either prospectively or retroactively.
This discussion does not address all of the tax consequences relating to the purchase, ownership, and disposition of ADSs and does not
take into account U. S. Holders who may be subject to special rules, including financial institutions, insurance companies, tax-exempt
organizations, real estate investment trusts, regulated investment companies, grantor trusts, non-resident aliens of the United States
or taxpayers whose functional currency is not the U. S. dollar, persons who hold the ADSs through partnerships or other pass-through entities,
persons who acquired their